Xylitol Chewing gum

PreclinicalSmall molecule

UUniversity of Washington

Xylitol Chewing gum is one of 3 small molecule programs targeting Preterm Birth. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Preterm BirthRecruiting

Preterm BirthPreclinical

Recruiting

Competition

Competitive Landscape

3 competitors in Preterm Birth

#DrugCompanyPhaseTrials

Azulfidine

Pfizer

Phase 2

1 2

Tractocile

GSK

Preclinical

1 3

Xylitol Chewing gum

UUniversity of Washington

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

PreclinicalRecruiting

Preterm Birth

NCT07424846

Clinical

Trials by Indication[1]

Preterm Birth1 trial

Xylitol and the Prevention of Periodontal Disease and Preterm Birth (XaPPP) Trial

Recruiting·UUniversity of Washington·Preclinical·NCT07424846·6,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Xylitol Chewing gum. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Xylitol Chewing gum compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Xylitol Chewing gum. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Washington company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Washington

Xylitol Chewing gum

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Preterm Birth1 trial

References

Drug Info

Quick Facts

Related News